BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1016 related articles for article (PubMed ID: 12535426)

  • 1. Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Mac Donald R; Rutks I
    Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WITHDRAWN: Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Macdonald R; Rutks I
    Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD002081. PubMed ID: 21901681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serenoa repens for benign prostatic hyperplasia.
    Wilt T; Ishani A; Mac Donald R
    Cochrane Database Syst Rev; 2002; (3):CD001423. PubMed ID: 12137626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terazosin for benign prostatic hyperplasia.
    Wilt TJ; Howe RW; Rutks IR; MacDonald R
    Cochrane Database Syst Rev; 2002; (4):CD003851. PubMed ID: 12519611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pygeum africanum for benign prostatic hyperplasia.
    Wilt T; Ishani A; Mac Donald R; Rutks I; Stark G
    Cochrane Database Syst Rev; 2002; 1998(1):CD001044. PubMed ID: 11869585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cernilton for benign prostatic hyperplasia.
    Wilt T; Mac Donald R; Ishani A; Rutks I; Stark G
    Cochrane Database Syst Rev; 2000; (2):CD001042. PubMed ID: 10796739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WITHDRAWN: Terazosin for benign prostatic hyperplasia.
    Wilt TJ; Howe RW; Rutks I; Macdonald R
    Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD003851. PubMed ID: 21901686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serenoa repens for benign prostatic hyperplasia.
    Wilt T; Ishani A; Stark G; MacDonald R; Mulrow C; Lau J
    Cochrane Database Syst Rev; 2000; (2):CD001423. PubMed ID: 10796790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serenoa repens for benign prostatic hyperplasia.
    Tacklind J; MacDonald R; Rutks I; Wilt TJ
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001423. PubMed ID: 19370565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finasteride for benign prostatic hyperplasia.
    Tacklind J; Fink HA; Macdonald R; Rutks I; Wilt TJ
    Cochrane Database Syst Rev; 2010 Oct; 2010(10):CD006015. PubMed ID: 20927745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Garimella PS; Fink HA; Macdonald R; Wilt TJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects.
    Wilt TJ; Howe W; MacDonald R
    BJU Int; 2002 Feb; 89(3):214-25. PubMed ID: 11856101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WITHDRAWN: Cernilton for benign prostatic hyperplasia.
    Wilt TJ; Macdonald R; Ishani A; Rutks I; Stark G
    Cochrane Database Syst Rev; 2011 May; 2011(5):CD001042. PubMed ID: 21563128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microwave thermotherapy for benign prostatic hyperplasia.
    Hoffman RM; Monga M; Elliot SP; Macdonald R; Wilt TJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD004135. PubMed ID: 17943811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serenoa repens for benign prostatic hyperplasia.
    Tacklind J; Macdonald R; Rutks I; Stanke JU; Wilt TJ
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD001423. PubMed ID: 23235581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
    Wilt TJ; MacDonald R; Nelson D
    J Urol; 2002 Jan; 167(1):177-83. PubMed ID: 11743300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phytotherapy for benign prostatic hyperplasia.
    Wilt TJ; Ishani A; Rutks I; MacDonald R
    Public Health Nutr; 2000 Dec; 3(4A):459-72. PubMed ID: 11276294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Hwang EC; Gandhi S; Jung JH; Imamura M; Kim MH; Pang R; Dahm P
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007360. PubMed ID: 30306544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; DamiĆ£o R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-sitosterols for benign prostatic hyperplasia.
    Wilt T; Ishani A; MacDonald R; Stark G; Mulrow C; Lau J
    Cochrane Database Syst Rev; 2000; 1999(2):CD001043. PubMed ID: 10796740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.